Black Diamond Therapeutics (BDTX) Preferred Stock Liabilities (2018 - 2019)

Black Diamond Therapeutics (BDTX) has reported Preferred Stock Liabilities for 2 consecutive years, with $200.6 million the latest figure, recorded in Q4 2019.

• For the quarter ending Q4 2019, Preferred Stock Liabilities rose 230.05% year-over-year to $200.6 million; the trailing twelve-month figure through Dec 2019 stood at $200.6 million (up 230.05% YoY), and the FY2019 full-year result was $200.6 million, up 230.05% from the prior year.
• Preferred Stock Liabilities climbed to $200.6 million in Q4 2019 per BDTX's latest filing, from $115.8 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $200.6 million in Q4 2019 and bottomed at $60.8 million in Q4 2018.